Navamedic adjusted EBITDA margin drops 1.9 percentage points to 5.5% in Q2 FY26; revenue rises 3.3% to NOK 278.3 million in H1 FY26

PUBT · 2d ago
Navamedic adjusted EBITDA margin drops 1.9 percentage points to 5.5% in Q2 FY26; revenue rises 3.3% to NOK 278.3 million in H1 FY26
  • Navamedic posted H1 2026 revenue of NOK 278.3 million, up 3.3% year on year, with gross margin of 38.9%.
  • Adjusted EBITDA margin rose 1.7 percentage points to 10.2% in H1 2026.
  • Q2 2026 EBITDA margin fell 1.9 percentage points to 5.5% due to CEO-change costs and inventory write-offs.
  • Q2 prescription drugs revenue rose to NOK 74.3 million, including NOK 14.5 million from the addiction portfolio acquired in July 2025.
  • Outlook: 2026 revenue seen around 2025 levels, with improved gross margins and EBITDA on product mix and operational efficiencies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Navamedic ASA published the original content used to generate this news brief via Cision (Ref. ID: 20260814:BIT:7708:0) on August 14, 2026, and is solely responsible for the information contained therein.